Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • DOP rejects Mylan...

    DOP rejects Mylan review application for revising retail price of Hepatitis B, HIV drug

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-18T15:58:36+05:30  |  Updated On 17 Aug 2021 12:38 PM IST

    New Delhi: Through a recent decision, the Department of Pharmaceuticals has rejected the review application filed by Mylan Pharmaceuticals Private Limited for reconsideration of the retail prices of Tenofovir Alafenamide Fumarate (TAF) 25mg tablet and Tenofovir Alafenamide Fumarate 25mg+Emtricitabine 200mg tablet, fixed by National Pharmaceutical Pricing Authority (NPPA).


    Tenofovir alafenamide is used to treat chronic hepatitis B infection, a viral infection of the liver. It works by stopping or slowing the growth of the virus while Tenofovir Alafenamide Fumarate in combination with Emtricitabine helps to decrease the amount of HIV in one's body so that the immune system can work better.


    Challenging NPPA's decision, Mylan contended that the Multidisciplinary Committee of Experts has failed to take into account critical facts and data in order to arrive at a holistic assessment of the price to be determined for Tenofovir Alafenamide Fumarate (TAF)


    The company stated that TAF falls under Explanation 5 in Schedule I of DPCO, 2013 which stipulates that in cases where an active moiety is available as different isomers or analogues or derivatives, they are considered separate entities, and inclusion of one does not imply inclusion of all isomers or analogues or derivatives. Thus inclusion of Tenofovir in the DPCO schedule does not automatically imply inclusion of all isomers, analogues and derivatives of the same.


    The company further stated that TAF falls under Explanation 2 in Schedule 1 of DPCO, 2013, which states that


    (i) innovation in medicine must be encouraged; and


    (ii) the formulations developed through incremental innovation or novel drug delivery systems like lipid/liposomal formulations, sustained-release/controlled release etc. should be considered as included only if specified in the list against any medicine. Such different formulations should be considered differently for purposes such as procurement policy, pricing etc.


    The company asked that for the purpose of determination of a price of new drug, mere therapeutic equivalence or, similar clinical efficacy as an existing formulation cannot be the sole basis and due regard has to be given to incremental innovations that have been made in a formulation, resulting in a novel formulation with improved drug delivery and better safety profile.


    The company sought to re-consider the price fixed for TAF and TAF plus Emtricitabine combination considering TAF as a novel formulation with incremental innovation in the formulation of Tenofovir, resulting in improved drug delivery and better safety profile.


    Commenting on the issue, NPPA stated that NPPA's Authority fixed the retail price of Tenofovir Alfenamide Fumarate (TAF) 25mg and Tenofovir Alfenamide Fumarate (TAF) 25mg+ Emtricitabine 200mg tablet based on the recommendation of Multidisciplinary Committee of Experts in its 8th Meeting held on 18.3.2019. While making the recommendation, the Multidisciplinary Committee of Expert has gone through all the technical matters submitted by the company.


    Deliberating the matter, the DOP stated that the issues relating to incremental innovation or novel drug delivery systems, sustained release/controlled release etc. in the formulations, therapeutic rationale and other related issues, are referred by NPPA to the Multidisciplinary Committee of Experts for examination and its recommendations. The Expert Committee is well represented by very senior Professors and Doctors and other experts in the field, who are capable enough to understand the therapeutic rationale of any drug/formulation.


    The matter of retail price fixation of the Tenofovir Alfenamide Fumarate (TAF) 25mg was discussed thrice (in its 6th, 7th and 8th meetings) by the Multidisciplinary Committee of Experts. The recommendation of the Committee was made on a scientific basis by comparing the therapeutic value of one pharmaceutical drug to another as per the provisions of the DPCO, 2013 and the Committee of Experts has rightly recommended the price of Tenofovir Alafenamide Fumarate (TAF) 25mg tablet and TAF plus Emtricitabine 200mg tablet, which has been subsequently fixed by NPPA.


    "In view of the above, the rationale put forth by the company in its review application for reconsideration of the matter by NPPA cannot be accepted and needs to be rejected," stated DOP order.


    "The review application filed by the applicant is devoid of any merit and hence stands rejected," the order added.


    Also Read: DOP Order: NPPA refixes retail price of Trilosar 6.25, 12.5
    Department of PharmaceuticalsDOP orderDPCO Schedule 1emtricitabineHIVMultidisciplinary CommitteeMylanNational Pharmaceutical Pricing Authoritynovel drugNPPApharmapharma news indiapharme newsTAFTAF+EmtricitabineTenofovir Alafenamide Fumarate

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok